Cargando…
Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma
Medulloblastoma (MB) is a common yet highly heterogeneous childhood malignant brain tumor, however, clinically effective molecular targeted therapy is lacking. Modulation of hedgehog (HH) signaling by epigenetically targeting the transcriptional factors GLI through bromodomain-containing protein 4 (...
Autores principales: | Liu, Xiaohua, Zhang, Yu, Li, Yalei, Wang, Juan, Ding, Huaqian, Huang, Wenjing, Ding, Chunyong, Liu, Hongchun, Tan, Wenfu, Zhang, Ao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893122/ https://www.ncbi.nlm.nih.gov/pubmed/33643826 http://dx.doi.org/10.1016/j.apsb.2020.07.007 |
Ejemplares similares
-
Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
por: Tang, Yujie, et al.
Publicado: (2014) -
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013) -
Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023) -
MBRS-02. BET BROMODOMAIN PROTEIN-KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF MEDULLOBLASTOMA
por: Ayad, Nagi, et al.
Publicado: (2020) -
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)